Rubraca® (rucaparib) – New indication
May 15, 2020 - Clovis Oncology announced the FDA approval of Rubraca (rucaparib), for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)¬-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Top